|
74. |
BMA and the Royal Pharmaceutical Society of Great Britain, op cit, p151. |
|
75. |
Henry, J. (ed.), The British Medical Association Gu ide to Medicines & Drugs, London, Dorling Kindersley, (2nd edn) 1991, p80. |
|
76. |
Feely, op cit, p307. |
|
77. |
Breggin, op cit, p199. |
|
78. |
Anon., "US group warnings on Prozac", Scrip, No 1533, 20 Jul 1990, p26. |
|
79. |
Anon., "Top 20 products in 1992", Scrip, No 1812/13, 16/20 Apr 1993, p29. |
|
80. |
Anon., "US FDA panel on Prozac - effect on litigation", Scrip, No 1656, 2 Oct 1991, p21. |
|
81. |
Potter, W.Z., Rudorfer, M.V., et al, "The pharmacological treatment of depression", New England Journal of Medicine, Vol 325, 29 Augl991, pp633-42. |
|
82. |
Breggin, op cit, p200. |
|
83. |
Levinson, M.L., Lipsy, R.J. and Fuller, D.K., "Adverse effects and drug interactions associated with fluoxetine therapy", DICP, The Annals of Pharmacotherapy, Vol 125, Jun 1991, pp657-61. |
|
84. |
Teicher, M.H., Glod, C., et al, "Emergence of intense suicidal preoccupation during fluoxetine treatment", American Journal of Psychiatry, Vol 147, 1990, pp206-10. |
|
85. |
Anon., "Prozac claims", Lancet, Vol 338, 3 Aug 1991, p307. |
|
86. |
Ahmad, S.R., "USA: fluoxetine 'not linked to suicide'", Lancet, Vol 338, 5 Oct 1991, pp875-6. |
|
87. |
Anon., Scrip, No 1656, op cit, p21. |
|
88. |
Breggin, op cit, p208. |
|
89. |
Anon., "Dr Moebius attacks Prozac enthusiasm", Scrip, No 1517, 25 May 1990, p27. |
|
90. |
Potter, et al, op cit. |
|
91. |
Feely, op cit, p303. |
|
92. |
Breggin, op cit, p211. |
|
93. |
Ibid, pp57-83. |
|
94. |
Monon, I., Hall, J. and Halliday, J., Tranquillisers: The comprehensive guide, London, Bloomsbury, 1992, ppxvi-xvii. |
|
95. |
Laurence, D.R. and Bennett, P.N., Clinical Pharmacology, Edinburgh, Churchill Livingstone, (6th edn), 1987, p362. |
|
96. |
Gilman, et al, op cit, p402. |
|
97. |
Wolfe, et al, op cit, p159. |